In partnership with the University of Alberta, Merck launched the Merck Invention Accelerator in a grand opening in Edmonton, Alberta, October 26, 2018. Pacylex was selected as one of the first 4 companies to participate in the accelerator program. This program consists of mentorship, space and funding https://www.tecedmonton.com/what-we-offer/programs-and-accelerators/merck-invention-accelerator/. Mentorship includes scientific and business input from Merck experts and mentorship from the TEC Health Accelerator program to help build, grow and scale PCLX-001. Common office and research space at TEC Edmonton is also provided along with direct access to all University of Alberta facilities. In addition, the company receives a small amount of non-dilutive funding to support the advancement of PCLX-001. This relationship does not require any equity or commercial rights from Pacylex.
One day prior to the Grand Opening (October 25), Pacylex CEO Michael Weickert, PhD, presented Pacylex at the LifeSciences BC’s Investor Summit in Vancouver (https://lifesciencesbc.ca/event/lifesciences-bc-investor-summit-2018-presented-by-lumira-ventures/). Pacylex was one of only 18 companies chosen to present. Co-sponsored by Lumira Ventures, the Investor Summit brought together stakeholders in the healthcare innovation ecosystem for a day of company pitches, panel discussions and entrepreneurs getting feedback and engagement from a wide range of investor stakeholders including; angel investors, venture capital, corporate ventures and funding foundations.